Edition:
United States

Acasti Pharma Inc (ACST.O)

ACST.O on Consolidated Issue listed on NASDAQ Capital Market

1.32USD
22 Sep 2017
Change (% chg)

$0.00 (+0.01%)
Prev Close
$1.32
Open
$1.32
Day's High
$1.35
Day's Low
$1.30
Volume
18,730
Avg. Vol
25,413
52-wk High
$2.46
52-wk Low
$1.11

Chart for

About

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $24.02
Shares Outstanding(Mil.): 14.74
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-Acasti Pharma reports Q1 loss per share c$0.19

* Acasti Pharma reports first quarter fy 2018 financial results

Aug 14 2017

BRIEF-Acasti Pharma issues common shares in payment of outstanding interest under debentures

* Acasti Pharma announces issuance of common shares in payment of outstanding interest under debentures Source text for Eikon: Further company coverage:

Jul 28 2017

BRIEF-Acasti Pharma reports Q4 and FY 2017 financial results

* Acasti Pharma reports fourth quarter and full-year 2017 financial results

Jun 06 2017

BRIEF-Acasti Pharma, CordenPharma announce large scale production of CaPre with new continuous manufacturing process

* Acasti Pharma and CordenPharma announce large scale production of Capre with new continuous manufacturing process Source text for Eikon: Further company coverage:

May 31 2017

BRIEF-Acasti Pharma says has successfully completed two Phase 1, two Phase 2 clinical trials with Capre

* Acasti Pharma Inc - has successfully completed two Phase 1 and two Phase 2 clinical trials with Capre for treatment of hypertriglyceridemia

Apr 12 2017

BRIEF-Acasti Pharma provides update on Capre phase 3 development program

* Acasti Pharma provides update on Capre phase 3 development program

Mar 30 2017

Earnings vs. Estimates